Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024. Praxis management will participate in a fireside chat at the Truist Securities BioPharma Symposium, ta ...